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doi:10.1016/j.jtcvs.2005.09.057bjectives: Unfractionated heparin and its antidote, protamine sulfate, allow for
apid and reversible anticoagulation during cardiac surgery with cardiopulmonary
ypass, yet limitations exist, including a variable dose-response, dependence on a
ofactor for anticoagulant effect, and antigenic potential. This trial was performed
o evaluate the safety and efficacy of bivalirudin as an alternative to heparin with
rotamine reversal in on-pump cardiac surgery.
ethods: We conducted a randomized, open-label, multicenter trial comparing
eparin with protamine reversal to bivalirudin in patients undergoing cardiac sur-
ery with cardiopulmonary bypass. The primary objective was to demonstrate
omparable rates of in-hospital procedural success defined as freedom from death,
-wave myocardial infarction, stroke, or repeat revascularization. Twenty-one
nstitutions enrolled 101 patients randomized to bivalirudin and 49 patients to
eparin treatment.
esults: The primary end point of procedural success was not significantly different
etween the bivalirudin arm and the heparin/protamine arms at 7 days, 30 days, or
2 weeks’ follow-up. Adequate anticoagulation was achieved in all patients. Sec-
ndary end points including mortality, 24-hour blood loss, overall incidence of
ransfusions, and duration of surgery were similar between the two arms.
onclusions: Bivalirudin is a safe and effective anticoagulant for patients undergo-
ng a wide range of cardiac surgical procedures with cardiopulmonary bypass.
rocedural success rates with bivalirudin were similar to rates in patients receiving
eparin anticoagulation, with no difference in mortality. Avoidance of blood stasis
nd attention to the intraoperative medical management of patients is critical for
uccessful use of bivalirudin during cardiopulmonary bypass.
nfractionated heparin (UFH) has been a cornerstone of cardiac surgery
since the first operation using cardiopulmonary bypass (CPB), and while
dramatic advances in surgical technique, anesthesia care, and perfusion
echnology have occurred since the early days of cardiac surgery, anticoagulation
trategies have not changed. UFH and its antidote, protamine sulfate, allow for rapid
nd reversible anticoagulation, yet limitations exist. UFH requires a cofactor (an-
ithrombin) for effect, resulting in variable patient response, heparin resistance, and
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A
CDepletion of antithrombin during bypass, which is associ-
ted with poorer outcomes in patients undergoing cardiac
urgery.1,2 UFH is also highly antigenic, provoking an an-
ibody response in approximately 40% of patients after
ardiac surgery and heparin-induced thrombocytopenia and
hrombosis syndrome (HIT/TS) in 1% to 2% of patients.3
he variable and dose-dependent clearance of UFH requires
eversal with protamine sulfate, which is antigenic as
ell.4-6 Protamine administration may result in clinical ad-
erse reactions, including systemic hypotension, pulmonary
ypertension, or anaphylaxis.5-8
Bivalirudin is a bivalent, reversible direct thrombin inhibi-
or with a relatively short half-life and is eliminated mainly by
proteolytic mechanism independent of renal or hepatic func-
ion. In several large trials, bivalirudin has been successfully
sed as a replacement for heparin during percutaneous coro-
ary intervention.9-11 During “off-pump” coronary artery by-
ass graft (CABG) surgery, the use of bivalirudin was associ-
ted with a comparable safety profile but improved graft
atency rates compared with heparin and protamine reversal.12
oreover, in a prior pilot investigation in patients undergoing
lective on-pump CABG surgery, the feasibility of bivalirudin
or anticoagulation during CPB has been established.13 Biva-
irudin, a 20 amino acid peptide with little secondary structure,
ppears to be nonimmunogenic.3,14,15
The EValuation of Patients during Coronary Artery By-
ass Graft Operation: Linking UTilization of Bivalirudin to
mproved Outcomes and New Anticoagulant Strategies
EVOLUTION-ON) trial was designed as a safety study to
ompare systemic anticoagulation with bivalirudin to UFH
ith protamine reversal in patients undergoing cardiac sur-
ery with CPB. The study is a component of a larger
rogram investigating the use of bivalirudin in patients
ndergoing on-pump and off-pump cardiac surgery, includ-
Abbreviations and Acronyms
ACT  activated clotting time
CABG  coronary artery bypass grafting
CPB  cardiopulmonary bypass
EVOLUTION-ON EValuation of Patients during
Coronary Artery Bypass Graft
Operation: Linking UTilization of
Bivalirudin to Improved
Outcomes and New
Anticoagulant Strategies
HIT/TS  heparin-induced
thrombocytopenia and
thrombosis syndrome
MI myocardial infarction
UFH  unfractionated heparinng those with HIT/TS or at risk for HIT/TS. m
34 The Journal of Thoracic and Cardiovascular Surgery ● Marcethods
tudy Population
his was a randomized, prospective, multicenter, open-label,
ctive-controlled study of bivalirudin versus UFH with protamine
eversal in patients undergoing cardiac surgery with planned CPB.
atients underwent a variety of procedures, including primary and
eoperative CABG, CABG plus valve surgery, or isolated valve
urgery. Although patients with severe renal failure were excluded,
atients with renal impairment (creatinine clearance30 mL/min)
ere allowed. Patients recently exposed to preoperative anticoag-
lant medications including glycoprotein IIb/IIa receptor antago-
ists, adenosine diphosphate receptor antagonists, low-molecular-
eight heparins, or thrombolytics were excluded. The study was
pproved by the institutional review board at each site. Informed
onsent was obtained from 150 patients at 21 sites in the United
tates and Germany. A computerized telephone system was used
o randomize patients to bivalirudin versus heparin/protamine with
2:1 ratio; 101 patients were randomized to bivalirudin and 49
atients to heparin/protamine. Three patients dropped out of the
ivalirudin arm after randomization but before surgery and were
eassigned to receive heparin. Accordingly, 98 patients received
ivalirudin and 52 patients received heparin as the sole anticoag-
lant during cardiac surgery with CPB. Data and summary statis-
ics are presented on the basis of this safety population.
linical End Points
he primary end point of the study was in-hospital procedural
uccess, defined as the absence of death, Q-wave myocardial
nfarction (MI), stroke, or repeat coronary revascularization. Sec-
ndary end points included non–Q-wave MI, transfusion require-
ents, major bleeding, thromboembolic events, change in renal
unction, and anticoagulation profile. Non–Q-wave MI was de-
ned as creatine kinase MB elevation 10 times or greater than the
ocal upper limit of normal if within 24 hours after surgery. If more
han 24 hours after cardiac surgery, the definition was creatine
inase MB elevation greater than the upper limit of normal on 2
uccessive samples, or creatine kinase MB greater than 2 times the
pper limit of normal on 1 occasion; and either ischemic symp-
oms or electrocardiographic changes indicative of ischemia. Ad-
udicated data from an independent and blinded clinical events
ommittee are used in all statistical analyses. Major bleeding was
efined as any intracranial or intraocular bleed, retroperitoneal
leeding, gastrointestinal bleeding, or persistent hemorrhage ne-
essitating re-exploration.
osing and Monitoring of Anticoagulation
or patients randomized to heparin/protamine, individual institu-
ional practices regarding dosing and protamine reversal were
sed. A summary of heparin and protamine doses are provided in
able 1.
For patients randomized to bivalirudin, a 1.0 mg/kg intravenous
olus followed by a 2.5 mg · kg1 · h1 infusion was used. Timing
f anticoagulation was routine and given at the request of the
urgeon when systemic anticoagulation was desired. The bivaliru-
in infusion dose was not titrated during CPB, although additional
oluses (0.1-0.5 mg/kg) were allowed at the discretion of the team.
otal bivalirudin doses are detailed in Table 1. An additional 50
g of bivalirudin was added to the priming solution of the CPB
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A
CDump. Sodium citrate was the anticoagulant used in the cell sal-
age device in both groups.
Anticoagulation was monitored at baseline, within 5 minutes of
rug administration, and thereafter according to standard institu-
ional practice regarding the type and frequency. For patients
eceiving bivalirudin, an initial activated clotting time (ACT) 2.5
imes the baseline was used as a guideline, based on the clotting
est routinely used by the institution. Additional bolus dosing was
eft to the discretion of the surgeon and anesthesiologist.
tatistical Analysis
he study was designed to evaluate the safety of bivalirudin as an
nticoagulant for patients undergoing cardiac surgery. Data were
ollected by The Medicines Company (Parsippany, NJ). Authors
ad full access to all data and were responsible for its interpreta-
ion, with approval rights over publication. All analyses were per-
ormed primarily on the “as-treated” (safety) population, defined as
atients categorized according to the anticoagulant received, irre-
pective of randomization. Descriptive statistics were used to
ummarize most of the data. Quantitative (continuous) variables
ere summarized by mean, standard deviation, median, interquar-
ile range, and minimum and maximum values. Qualitative (cate-
orical) variables were summarized by frequencies and percent-
ges. Owing to the small number of patients in each group,
xploratory nonparametric tests (Fisher exact test for categorical
ariables, Wilcoxon rank-sum test for continuous variables) were
ABLE 1. Summary of drug administration
Bivalirudin;
N  98 (mg/kg)
Heparin  protamine;
N  52 (units/kg)
nitial bolus dose
Mean  SD 1.0 0.0 344.2 101.3
Median 1.0 343.5
(minimum, maximum) (1, 1) (57, 615)
nitial infusion rate
Mean  SD 2.5 0.2 0
Median 2.5 0
(minimum, maximum) (1, 3)
otal bolus dose
Mean  SD 1.0 0.1 440.5 209.1
Median 1.0 401.1
(minimum, maximum) (1, 2) (143, 1442)
otal drug dose*
Mean  SD 5.0 1.6 440.5 209.1
Median 4.5 401.1
(minimum, maximum) (2, 9) (143, 1442)
otal protamine dose (mg/kg)
Mean  SD N/A 3.7 1.5
Median N/A 3.6
(minimum, maximum) (0, 7)
nitial and total anticoagulation doses are detailed for patients receiving
eparin/protamine and bivalirudin. Total dosing reflects additional boluses
eceived during cardiopulmonary bypass. SD, Standard deviation; N/A, not
vailable. *Includes 50 mg administered as the pump prime.sed to calculate P values. m
The Journal of Thoracicesults
esults are presented for the safety population of this trial;
ntent-to-treat analysis provided very similar results. Demo-
raphic and medical history data are presented in Table 2.
edian age between the two groups was similar, with a
lightly higher percentage of women in the heparin/prota-
ABLE 2. Demographics, pertinent medical history, and
rocedures performed
arameter
Bivalirudin
(N  98)
Heparin 
protamine (N  52)
ge (y); mean  SD 63.9 11.0 65.1 9.8
ge group, n (%)
65 y 48 (49.0) 24 (46.2)
65 y 50 (51.0) 28 (53.8)
ge group, n (%)
75 y 83 (84.7) 42 (80.8)
75 y 15 (15.3) 10 (19.2)
ex, n (%)
Male 78 (79.6) 36 (69.2)
Female 20 (20.4) 16 (30.8)
eight (kg)
Mean  SD 87.8 15.0 85.5 20.4
Median 85.5 86
(minimum, maximum) (56, 128) (45, 141)
edical history
resented with angina, n (%) 69 (70.4) 26 (50.0)
Stable, n/N (%) 27/69 (39.1) 10/26 (38.5)
Unstable, n/N (%) 42/69 (60.9) 16/26 (61.5)
istory of MI, n (%) 18 (18.4) 14 (26.9)
rior PCI procedure, n (%) 20 (20.4) 13 (25.0)
ongestive heart failure, n (%) 15 (15.3) 9 (17.3)
iabetes, n (%) 36 (36.7) 15 (28.8)
solated CABG 70 (71.4%) 35 (67.3%)
No. of grafts N  85 N  46
Mean  SD 3.2  1.0 3.0  1.0
Median 3.0 3.0
(minimum, maximum) (1, 5) (1, 5)
ombined CABG/valve
operation
10 (10.2%) 8 (15.4%)
CABG/AVR prosthesis 5 4
CABG/AVR repair 0 1
CABG/MVR prosthesis 2 2
CABG/MVR repair 3 1
ny CABG LITA use rate 73/87 (84%) 39/44 (89%)
solated valve operation 12 (12.2%) 6 (11.5%)
AVR 10 3
MVR 2 3
ther 6 (6.1%) 3 (5.8%)
atients were evenly matched between groups. In both groups, the num-
er of men predominated. The incidence of significant comorbidities was
imilar between groups. SD, Standard deviation; MI, myocardial infarction;
CI, percutaneous coronary intervention; CABG, coronary artery bypass
rafting; AVR, aortic valve replacement; MVR, mitral valve replacement;
ITA, left internal thoracic artery.ine arm than in the bivalirudin arm. The incidence of
and Cardiovascular Surgery ● Volume 131, Number 3 535
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A
CDomorbid risk factors was comparable between groups. Ap-
roximately 70% of patients in both groups underwent
solated CABG. Table 2 provides a summary of procedures
erformed. Crystalloid cardioplegia was used in 25 patients
igure 1. Procedural success. Procedural success, defined as the
reedom from death, Q-wave MI, stroke, or revascularization, was
ot significantly different between groups at 7 days, 30 days, or 12
ABLE 3. Intraoperative details
arameter
Bivalirudin
(N  98)
Heparin  protamine
(N  52)
uration of surgery (min)* N  98 N  52
Mean  SD 243.7 91.7 241.7 99.1
Median 229.0 220.5
(minimum, maximum) (113, 665) (111, 540)
uration on CPB N  7 N  50
Mean  SD 85.3 37.4 89.0 51.2
Median 75.0 76.0
(minimum, maximum) (30, 194) (27, 365)
rossclamp time N  94 N  49
Mean  SD 61.9 23.6 67.7 28.2
Median 58.0 68.0
(minimum, maximum) (23, 123) (27, 181)
uration from end of CPB
to chest closure†
N  97 N  50
Mean  SD 71.2 40.1 56.6 29.3
Median 60.0 50.5
(minimum, maximum) (21, 290) (21, 175)
oronary artery bypass grafting was the most common procedure in both
roups. The duration of cardiopulmonary bypass (CPB) and the crossclamp
ime was similar between groups. While the time from the end of CPB to
hest closure was longer in the bivalirudin group, the overall duration of
urgery was similar. SD, Standard deviation. *Start of surgery to operating
oom exit. †P  .015. All other P values  not significant.Meeks after surgery.
36 The Journal of Thoracic and Cardiovascular Surgery ● Marc48%) receiving heparin and 52 patients (53%) receiving
ivalirudin. A blood-based cardioplegic solution was used
n 24 patients (46%) receiving heparin and 42 patients
43%) receiving bivalirudin; the type of cardioplegia used in
he remainder is unknown. The duration of CPB was similar
etween groups (Table 3). The time interval from the end of
PB until chest closure was longer in patients receiving
ivalirudin anticoagulation (71.2 vs 56.6 minutes, P 
015), although the total operative time was not different
etween groups. Additional intraoperative details are out-
ined in Table 3.
The primary end point of procedural success was not
ignificantly different between the bivalirudin arm and the
eparin/protamine arms at 7 days, 30 days, or 12 weeks
Figure 1). Thirty-day mortality was also not significantly
ifferent between groups, with 3 deaths in the bivalirudin
rm (3.1%; attributed to coronary artery disease, cardiac
amponade, and multisystem organ failure) and 1 death in
he heparin/protamine arm (1.9%; attributed to right atrial
nd inferior vena cava disruption). One additional patient in
he heparin/protamine arm died after 30 days, such that the
2-week mortality was 3.1% in the bivalirudin group and
.9% in the heparin/protamine group.
Six patients in the bivalirudin group and 6 patients in the
eparin group (6.1% vs 11.5%; P .34) had a perioperative
I 7 days after surgery (Figure 2). The incidence of Q-wave
igure 2. Perioperative MI. Although fewer patients receiving
ivalirudin had an MI, the study was not adequately powered to
etect a difference in rates of MI between groups. The incidence
f perioperative Q-wave and non–Q-wave MI was not signifi-
antly different between patients receiving with heparin (Hep) or
ivalirudin (Biv) anticoagulation.I (1/98 [1.0%] vs 1/52 [1.9%]; P  .999) was similar
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A
CDetween patients receiving bivalirudin or heparin, respec-
ively. There was a numerically lower incidence of non–Q-
ave MI in patients receiving bivalirudin compared with
eparin (5.1% vs 9.6%; P .32), although this difference
as not statistically significant. Thirty-day and 12-week MI
vent rates were similar to those at 7 days. The incidence of
troke was also similar between the bivalirudin and heparin
roups (1.1% vs 2.0% at 30 days and 12 weeks).
Cumulative blood loss at 2 and 24 hours postoperatively
s detailed in Figure 3. Early median blood loss was 78 mL
igher in patients receiving bivalirudin for anticoagulation
ompared with heparin/protamine (238 mL vs 160 mL; P
0009). However, by 24 hours this difference was no longer
tatistically significant (793 mL vs 668 mL; P  .15). In
ddition, there was significant heterogeneity between clini-
al sites in the volume of postoperative blood loss. Using
he predetermined definition, major bleeding occurred in
% of patients receiving bivalirudin and 2% of patients
eceiving heparin/protamine (P  .67). This difference was
riven by the difference in postoperative re-exploration
etween the bivalirudin and heparin/protamine groups (6/98
6.1%] vs. 1/52 [1.9%]; P  .67). For patients undergoing
ABG only, there was no difference in major bleeding
etween groups (2/75 [2.7%] vs 1/38 [2.6%]; P  .999,
ivalirudin vs heparin, respectively). There was no differ-
nce in intracranial, gastrointestinal, intraocular, or retro-
eritoneal bleeding between groups.
The incidence of perioperative complications was low
nd similar between groups. The incidence of transfusion
as not different between groups (Table 4). A total of 57
atients (58%) receiving bivalirudin and 31 (60%) patients
eceiving heparin/protamine received any transfusion dur-
ng their hospitalization. Although significant variability s
The Journal of Thoracicxisted among clinical sites, the median number of packed
ed blood cell units transfused per patient was 1.0 unit
igher in patients receiving bivalirudin anticoagulation. The
ncidence of platelet transfusion was also higher in patients
eceiving bivalirudin anticoagulation (Table 4), although
his difference was not statistically significant (P  .86).
Bivalirudin was an effective anticoagulant during CPB.
he 1.0 mg/kg bivalirudin bolus and 2.5 mg · kg1 · h1
nfusion resulted in a rapid and sustained increase in ACT.
ewer patients required reloading after the initial bolus in
he bivalirudin group than in the heparin group (9.2% vs
8.5%). Eight patients (8.2%) received an additional bolus
f bivalirudin during CPB and the infusion was adjusted in
Figure 3. Postoperative chest
tube output. Median and mean
postoperative chest tube output
was higher for the bivalirudin
treatment group at 2 hours (P 
.0009) and was not significantly
different between groups at 24
hours (P  .13), although signif-
icant variability existed and out-
liers were present in both
groups.
ABLE 4. Summary of transfusion requirements
Bivalirudin;
N  98; n (%)
Heparin  protamine;
N  52; n (%)
atients who had any
transfusion
57 (58.2) 31 (59.6)
ransfusion product
RBCs 56 (57.1) 27 (51.9)
latelets 19 (19.4) 5 (9.6)
resh frozen plasma 27 (27.6) 12 (23.1)
ther 7 (7.1) 3 (5.8)
atients who received
PRBCs 2 units
50 (51.0) 23 (44.2)
atients with repeat
exploratory operations
6 (6.1) 1 (1.9)
ransfusion practices were left to the discretion of the surgical team. A
ignificant number of patients in both groups received a transfusion,
lthough the incidence was similar. The re-exploration rates were not
ignificantly different between groups. PRBC, Packed red blood cell.
and Cardiovascular Surgery ● Volume 131, Number 3 537
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A
CD(7.1%) patients. No incident of thrombosis within the
xygenator, arterial line, or cardioplegia line occurred in the
tudy. In 2 patients receiving bivalirudin anticoagulation,
lot formation was observed within the venous reservoir,
ith no adverse consequences. In 6 cases, clot formation
as observed in the cell salvage device (separate from the
PB circuit). Atrial fibrillation was reported in 9.6% of
atients receiving heparin and 9.2% of patients receiving
ivalirudin. Acute renal failure occurred in 2 patients in the
eparin and bivalirudin groups, respectively (3.8% vs 2.0%).
iscussion
VOLUTION-ON is the first prospective, randomized trial
emonstrating similar efficacy and safety using an alterna-
ive anticoagulant for patients undergoing cardiac surgery
ith CPB. Our data provide further convincing evidence for
he feasibility for anticoagulation with bivalirudin during
ardiac surgery with CPB. Procedural success rates with
ivalirudin were similar to the rates with anticoagulation
ith heparin and protamine reversal, and the use of biva-
irudin as the sole anticoagulant during CPB did not ad-
ersely affect mortality at 7 days, 30 days, or 12 weeks.
imilarly, perioperative MI and other complications were
ot significantly different between groups at 7 and 30 days
fter surgery.
Although the incidence of MI between groups did not
each statistical significance, numerically fewer non–Q-
ave MIs were present in patients receiving bivalirudin.
ecent data have demonstrated that the magnitude of bi-
marker release after surgery correlates with outcomes and
re more predictive of serious adverse outcomes than the
resence of new Q waves.16,17 Additionally, heparin di-
ectly activates platelets18 and potentiates platelet activa-
ion, which may be problematic in patients with acute cor-
nary syndromes requiring surgery.19 Whether the more
redictable thrombin inhibition afforded by bivalirudin re-
ults in less myocardial injury during CABG with CPB
equires further investigation.
Anticoagulation with bivalirudin was predictable and con-
istent. The reliable pharmacokinetic profile of bivalirudin
as exemplified by the low number of patients requiring
eloading or adjustment of infusion during CPB, and no
atient in either group had difficulties with clot formation
ithin the oxygenator or arterial side of the pump circuitry.
n areas of stasis or in areas isolated from the circuit,
ivalirudin levels may be depleted owing to metabolism by
hrombin. Efforts to reduce stasis within the venous reser-
oir (such as the use of a closed system or temporary blood
torage within citrate-phosphate-dextrose bags) can be ef-
ective strategies to assure adequate levels of bivalirudin
nd prevent clot formation. The use of bivalirudin as an anti-
oagulant in the cell salvage device has not been evaluated. f
38 The Journal of Thoracic and Cardiovascular Surgery ● MarcThe choice of ACT instrument and type of test was left
o the institution and included Hemochron ACT kaolin
ITC, a subsidiary of Thoratec Corporation, Pleasanton,
alif), ecarin clotting time, ACT, and ACT-T. All ACT
ests used appeared to be effective tools for monitoring
nticoagulation with bivalirudin. The initial bivalirudin
olus resulted in rapid prolongation of the ACT, which
as maintained throughout the duration of CPB without
he need for significant dose adjustment. This ability to
uccessfully provide anticoagulation for patients with
inimal variability allows for weight-based dosing with
ivalirudin, in contrast to heparin. The ACT declined
ore rapidly after heparin reversal with protamine than
ith bivalirudin, as the majority of clearance of bivaliru-
in is through proteolytic cleavage. However, this did not
dversely affect the duration of surgery (a difference of
.5 minutes), and the median duration from the end of
PB to the end of surgery was also only 9.5 minutes
onger in patients with bivalirudin anticoagulation. This
as somewhat surprising, as more rapid hemostasis
ight be expected with heparin, given its immediate
eversibility with protamine. The similar chest closure
ime may reflect the short half-life of bivalirudin, which
ifferentiates it from other direct thrombin inhibitors.
Cumulative median blood loss within the first 24 hours
as not excessive in either the heparin or bivalirudin
roup and was similar to other large, prospective, ran-
omized trials in which postoperative bleeding was quan-
ified.20,21 In patients receiving bivalirudin anticoagula-
ion, there was increased blood loss (with significant
ariability) in the early postoperative period. Other early
ostoperative events such as platelet transfusion and re-
xploration for persistent hemorrhage were more fre-
uent in patients receiving bivalirudin, although the total
umber of patients was small and the differences in
latelet transfusion and re-exploration rates were not
tatistically significant. Unfamiliarity with bivalirudin
nd the more gradual return to hemostasis in these pa-
ients may have triggered early platelet use. Other caus-
tive factors for early postoperative bleeding may include
nappropriate reloading during CPB. However, the rates
f platelet transfusion in both groups were in line with
ational norms: 0% to 36% as reported in a study of 24
cademic institutions across the United States22 and
4.4% as reported in a study analyzing data from 6
ouble-blind aprotinin clinical trials performed for licen-
ure.23 Careful attention to the medical management and
erfusion management of patients with bivalirudin anti-
oagulation could minimize early blood loss.
The limitations of the study include its small size and
pen-label design. No attempt was made to control trans-
usion triggers or clinical practice among sites.
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CDonclusions
ivalirudin is a safe and effective anticoagulant for patients
ndergoing a wide range of cardiac surgical procedures with
PB. Procedural success rates with bivalirudin were similar
o those with heparin anticoagulation. Patients receiving
ivalirudin also had acceptable clinical outcomes, with no
ifference in mortality or complications after surgery. The
rend toward fewer MIs in patients receiving bivalirudin
uggests a need for further evaluation in adequately pow-
red, prospective clinical trials. Although bivalirudin is an
ffective anticoagulant, its pharmacodynamic profile re-
uires attention to medical management to reduce early
ostoperative bleeding and transfusion.
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